Characterization of SNARE Cleavage Products Generated by Formulated Botulinum Neurotoxin Type-A Drug Products
2010

Study of Botulinum Neurotoxin Type-A Drug Products

publication Evidence: moderate

Author Information

Author(s): Hunt Terrence, Rupp David, Shimizu Gary, Tam Karen, Weidler Julia, Xie Jack

Primary Institution: Allergan, Inc.

Hypothesis

The study aims to evaluate the substrate cleavage products generated by different botulinum neurotoxin type-A drug products.

Conclusion

The study found that incobotulinumtoxinA produced an atypical secondary cleavage product not observed in other tested drug products.

Supporting Evidence

  • IncobotulinumtoxinA generated two cleavage fragments instead of the expected single fragment.
  • Normal cleavage was observed for all other BoNT/A drug product samples.
  • The study utilized a novel LCA-HPLC method to detect and quantify cleavage products.

Takeaway

This study looked at how different botulinum toxin products work and found that one of them behaves differently than expected.

Methodology

The study used a light-chain activity high-performance liquid chromatography (LCA-HPLC) method to analyze the cleavage products of three botulinum neurotoxin type-A drug products.

Limitations

The study does not specify the limitations of the findings.

Digital Object Identifier (DOI)

10.3390/toxins2082198

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication